APTN · XBRL financial data

Adaptin Bio financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (APTN's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Research and development	—	—	199	685	683	258*	62	340	779	593*	166	138
General and administrative	43	34*	57	36	30	33*	788	1,181	897	775*	979	1,062
Total operating expenses	—	—	300	767	995	508*	850	1,521	1,676	1,368*	1,144	1,201
Operating income (loss)	(43)	(34)*	(300)	(767)	(995)	1,906*	(850)	(1,521)	(1,676)	(1,368)*	(1,144)	(1,201)
Interest expense	—	—	40	49	107	(189)*	73	0*	0*	0*	2	5
Net income (loss)	(43)	(34)*	(57)	(36)	(30)	(39)*	(603)	(1,521)	(1,676)	(1,368)*	(1,146)	(1,205)
Earnings per share, basic USD per share	(0.01)	(0.01)*	(0.01)	(0.01)	(0.01)	(0.01)*	(0.10)	(0.18)	(0.20)	(0.16)*	(0.13)	(0.14)
Earnings per share, diluted USD per share	(0.01)	(0.01)*	(0.01)	(0.01)	(0.01)	(0.01)*	(0.10)	(0.18)	(0.20)	(0.16)*	0.13	(0.14)
Weighted average shares, basic thousands of shares	5,000	5,000*	5,000	5,000	5,000	5,000*	5,827	8,455	8,456	8,475*	8,702	8,849
Weighted average shares, diluted thousands of shares	5,000	5,000*	5,000	5,000	5,000	5,000*	5,827	8,455	8,456	8,475*	8,702	8,849

Fiscal quarters (APTN's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	0	0	0	0	0	34	2,374	1,352	579	459	301	670
Prepaid and other current assets	—	—	—	—	—	11	—	—	400	160	405	311
Total current assets	0	0	0	0	0	13	2,854	1,663	979	619	706	981
Total assets	0	0	0	0	0	13	2,854	1,663	979	619	706	981
Accounts payable	—	—	—	—	—	1,361	327	667	1,338	1,512	1,371	1,674
Accrued liabilities	—	—	—	—	—	1,050	782	522	522	596	870	811
Total current liabilities	79	113	170	206	236	287	1,109	1,188	1,861	2,109	2,482	2,647
Total liabilities	79	113	170	206	236	287	1,109	1,188	1,861	2,109	2,482	2,647
Accumulated deficit	(79)	(113)	(171)	(206)	(236)	(275)	(4,727)	(6,248)	(7,924)	(9,292)	(10,438)	(11,643)
Total stockholders' equity	(79)	(113)	(170)	(206)	(235)	(274)	1,745	474	(881)	(1,489)	(1,776)	(1,665)
Total liabilities and equity	0	0	0	0	0	13	2,854	1,663	979	619	706	981
Common shares outstanding (cover page) thousands of shares	5,000	5,000	5,000	5,000	5,000	8,401	8,456	8,456	8,456	8,786	8,851	9,234

Fiscal quarters (APTN's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(43)	(34)*	(57)	(36)	(30)	(39)*	(603)	(1,521)	(1,676)	(1,368)*	(1,146)	(1,205)
Stock-based compensation	—	—	—	—	—	—	—	—	—	177*	345	194*
Net cash from operating activities	—	(58)*	(90)	58*	(25)*	(125)*	(2,280)	(1,023)*	(772)*	(703)*	(596)	(450)*
Proceeds from issuing common stock	—	—	—	—	—	—	—	—	—	—	652	260*
Net cash from financing activities	—	58*	90	(59)*	25*	137*	4,620	0*	0*	583*	438	819*

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Adaptin Bio	670	not reported	(450)*	9.2M	1.5 quarters	Q2 FY26 10-QJun 30, 2026
Artelo Biosciences	4,198	not reported	(5,033)*	4.6M	0.8 quarters	Q2 FY26 10-QJun 30, 2026
Bioxytran	177	not reported	(350)*	114.7M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Raphael Pharmaceutical	1	not reported	0*	20.2M	—	Q2 FY26 10-QJun 30, 2026
Oncotelic Therapeutics	186	250	(92)*	457.5M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
TherapeuticsMD	9,189	not reported	not reported	11.6M	—	Q2 FY26 10-QJun 30, 2026
Alaunos Therapeutics	124	0	(300)*	2.5M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
BioCardia	4,117	not reported	(1,735)*	15.1M	2.4 quarters	Q2 FY26 10-QJun 30, 2026
Traws Pharma	5,016	not reported	(7,504)*	15.4M	0.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.